EN | TR
E-ISSN: 3061-9947
Investigation of The Effect of Adjuvant Endocrine Treatment on Depression, Sleep Quality and Sexual Function in Hormone Receptor-Positive Early-Stage Breast Cancer
PDF
Cite
Share
Request
Original Article
VOLUME: 56 ISSUE: 3
P: 198-209
2023

Investigation of The Effect of Adjuvant Endocrine Treatment on Depression, Sleep Quality and Sexual Function in Hormone Receptor-Positive Early-Stage Breast Cancer

Acta Haematol Oncol Turc 2023;56(3):198-209
DOI: 10.5505/aot.2023.24654
Yağmur Kınacı Gümüşçubuk 1
Mutlu Hızal 2
Muhammed Bulent Akıncı 2
Bülent Yalçın 2
Oğuzcan Gümüşçubuk 3
Mehmet Ali Nahit Şendur 2
1. Hacettepe University Faculty Of Medicine, Department Of Public Health, Ankara, Turkey
2. Ankara City Hospital, Department Of Medical Oncology, Ankara, Turkey
3. Ankara Etlik City Hospital, Department Of Hematology, Ankara, Turkey
4.
No information available.
No information available
Received Date: 2022-11-28T15:34:32
Accepted Date: 2023-12-04T07:23:01
PDF
Cite
Share
Request

Abstract

INTRODUCTION

Questioning and recognizing depression, sleep and sexual dysfunctions in breast cancer patients improves the patients' quality of life. We aimed to evaluate the effects of adjuvant endocrine treatment and other variables on depression, sleep quality and sexual dysfunction in patients with early-stage breast cancer.

METHODS

Our study was performed with the participation of 105 patients who were diagnosed with hormone receptor positive, early stage (stage I-III) breast cancer and at least 3 months followed by the medical oncology outpatient clinic. Sociodemographic form, Beck Depression Inventory (BDI), Pittsburgh Sleep Quality Index (PSQI) and Female Sexual Function Index (FSFI) were used as data collection tools.

RESULTS

According to the results obtained in our study, 55.8% patients had depression, 60.6% patients had poor sleep quality, 77.1% had poor sexual function. A tendency to sexual dysfunction was observed in patients with PR positivity and it was found to be statistically significant (P=0.005). There was a strong (p<0.001) correlation between the PSQI and BDI values of the patients. There was no significant relationship between different endocrine therapy agents (tamoxifen/anastrozole/letrozole) in patients with depression, sleep and sexual dysfunction (p> 0.05).

DISCUSSION AND CONCLUSION

In our study, we found a tendency to depression, sleep disturbance, and sexual dysfunction in most patients. It was revealed that some sociodemographic features, adjuvant treatment and hormone receptor status may affect sexual functionality. Therefore, these symptoms should be questioned in patients followed up with a diagnosis of breast cancer.